

## LIST OF TABLES

Table 1. 1: Clinically used antipsychotic drugs with their trade names .....	2
Table 2. 1: Clinically used antipsychotic drugs with their trade names .....	14
Table 2. 2: Susceptible genes in schizophrenia .....	17
Table 2. 3: RNAi based drugs in clinical trials .....	22
Table 2. 4: List of patents for nose to brain delivery .....	39
Table 3. 1: Concentration of siRNA at 260 nm .....	56
Table 3. 2: Accuracy determination for UV spectrophotometric method .....	57
Table 3. 3: Interday and Intraday precision of the UV spectroscopic method .....	58
Table 3. 4: Band volume of siRNA at different concentrations .....	61
Table 3. 5: Band volume (x1000) of 100 pmole siRNA.....	62
Table 4. 1: Molecular weight of polymer/ copolymer/ conjugates .....	89
Table 4. 2: Conjugation ratio synthesized copolymers/ conjugates.....	90
Table 5. 1: Conjugation efficiency of different vectors .....	104
Table 5. 2: Particle size of polyplexes and lipopolyplexes .....	104
Table 5. 3: Zeta potential of vectors, polyplexes and lipopolyplexes.....	113
Table 5. 4: Results of heparin competition assay of different formulations.....	116
Table 5. 5: % nasal permeation of different formulations through sheep nasal mucosa .....	119
Table 6. 1: Characteristics of selected primers .....	134
Table 6. 2: Composition of cDNA synthesis reaction mixture .....	136
Table 6. 3: RT-PCR cycle .....	136
Table 6. 4: % cell viability of synthesized copolymers and conjugates .....	137
Table 6. 5: Papp values of different formulations and their enhancement ratio .....	139
Table 6. 6: Summary of results of quantitative cellular uptake .....	142
Table 6. 7: % NRG1 expression and knockdown efficiency of different treatment groups estimated by RT-PCR .....	143
Table 7. 1: Excipients used in nasal spray .....	149
Table 7. 2: Marketed nasal spray formulations.....	150
Table 7. 3: Optimized formula for nasal spray .....	151
Table 7. 4: Criteria for passing the microbial limit test for nasal spray.....	155
Table 7. 5: Criteria of tested microorganism for passing the preservative efficacy test .....	155

Table 7. 6: Viscosity of nasal spray formulation .....	156
Table 7. 7: Pump delivery volume for nasal spray pump .....	157
Table 7. 8: % Pump delivery for nasal spray pump .....	157
Table 7. 9: % Pump delivery volume for nasal spray pump to determine effect of resting time .....	162
Table 7. 10: Data depicting ovality ratio of nasal spray at 3 cm and 6 cm.....	164
Table 7. 11: Influence of spraying angle on various parameters of droplet size distribution .....	166
Table 7. 12: Influence of actuation force on various parameters of droplet size distribution .....	168
Table 7. 13: Influence of actuation distance on various parameters of droplet size distribution .....	169
Table 7. 14: Influence of hold time on various parameters of droplet size distribution .....	171
Table 7. 15: Optimized actuation parameters for preferable droplet size distribution .....	171
Table 7. 16: Optimized droplet size distribution parameters .....	172
Table 7. 17: Influence of time on weight of nasal spray pump.....	172
Table 7. 18: Droplet size distribution parameters as tail-off characteristics.....	173
Table 7. 19: Data depicting ovality ratio of nasal spray at 3 cm and 6 cm.....	174
Table 7. 20: Results of preservative efficacy study depicting colony forming units/ml of different microorganisms at sampled time points.....	176
Table 7. 21: Results of preservative efficacy study depicting log reduction of different microorganisms at sampled time points when compared with 0 days.....	176
Table 8. 1: Composition of lysis buffer (NP-40 buffer) .....	182
Table 8. 2: Composition of 2x Laemmli buffer .....	183
Table 8. 3: Composition of transfer buffer .....	184
Table 8. 4: Composition of stripping buffer .....	185
Table 8. 5: Composition of TBST buffer .....	185
Table 8. 6: % brain distribution of different formulations.....	187
Table 8. 7: % NRG1 expression of different treatment groups using western blotting .....	189
Table 8. 8: % NRG1 expression and knockdown efficiency of different treatment groups estimated by RT-PCR .....	190

Table 9. 1: Storage conditions of prepared formulations for stability study .....	194
Table 9. 2: Stability data of physicochemical properties of nasal spray.....	195
Table 9. 3: Droplet size distribution parameters of nasal spray at stability time points .....	197